G
GPN Vaccines
Creating a comprehensive vaccine targeting Streptococcus pneumoniae, the leading bacterial pathogen worldwide
About GPN Vaccines
GPN Vaccines is a clinical-stage biotechnology company developing a vaccine against Streptococcus pneumoniae, a bacterium that causes diseases such as pneumonia, meningitis, and sepsis. The company's main product is Gamma-PN, a vaccine that provides broad-spectrum protection against all strains of S. pneumoniae.
The business model of GPN Vaccines is focused on the development and commercialization of Gamma-PN. This includes conducting clinical trials, obtaining regulatory approvals, and establishing manufacturing and distribution channels. The company may also partner with larger pharmaceutical companies to bring the vaccine to market.
The target market for Gamma-PN includes individuals at high risk of pneumococcal disease, such as young children, the elderly, and people with weakened immune systems. The vaccine will be sold to healthcare providers, hospitals, and government agencies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Adelaide, Australia
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 89.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2024 | $12M | $194M | Kern Capital · Shearwater Capital · Forefront Capital Partners | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | $5.8M | $23M | Forefront Capital Partners | ↗ |
Growth signals
Latest recorded traffic for GPN Vaccines is 1.6K monthly website visits, down 46.7% over the last three months. GPN Vaccines's team grew 29.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Health and Medical Research Council
Government of South Australia
Series A4 investors entered at this stage
Forepont Capital Partners
Shearwater Capital
Forefront Capital Partners- KCKern Capital
Other known investors1 additional known investor
Southern Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GPN Vaccines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GPN Vaccines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.